Patents by Inventor Dominique Ingrid Lemoine
Dominique Ingrid Lemoine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220152182Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to immunogenic compositions and vaccines comprising detoxified pneumolysin adsorbed onto aluminium phosphate and an improved process for the adsorption of detoxified pneumolysin onto aluminium phosphate. It additionally relates to the use of the immunogenic compositions and vaccines in the treatment or prevention of Streptococcus pneumoniae infection.Type: ApplicationFiled: January 31, 2022Publication date: May 19, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Laurence Danielle GHENNE, Dominique Ingrid LEMOINE, Frédéric MATHOT, Florence Emilie Jeanne Francoise WAUTERS
-
Patent number: 11304999Abstract: Composition are described, which are dried under reduced pressure from a liquid mixture comprising an adjuvant comprising a saponin (e.g., such as QS21) in a liposomal formulation wherein the liposomes contain a neutral lipid (e.g., such as a phosphatidylcholine) and a sterol (e.g., such as cholesterol), and, a cryoprotectant that is an amorphous sugar. The adjuvant may further comprises a TLR-4 agonist. The compositions may further comprising an antigen, such as an antigen derived from Plasmodium falciparum, Mycobacterium tuberculosis, HIV, Moraxella, ntHi or Varicella Zoster Virus. The cryoprotectant is an amorphous sugar or mixture of amorphous sugars, and preferably is a combination of at least two cryoprotectants selected from sucrose, trehalose and dextran. The compositions may further comprise a buffer and/or a surfactant.Type: GrantFiled: May 22, 2020Date of Patent: April 19, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Dominique Ingrid Lemoine, Nicolas Moniotte
-
Patent number: 11266731Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to immunogenic compositions and vaccines comprising detoxified pneumolysin adsorbed onto aluminium phosphate and an improved process for the adsorption of detoxified pneumolysin onto aluminium phosphate. It additionally relates to the use of the immunogenic compositions and vaccines in the treatment or prevention of Streptococcu pneumoniae infection.Type: GrantFiled: February 20, 2017Date of Patent: March 8, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Laurence Danielle Ghenne, Dominique Ingrid Lemoine, Frédéric Mathot, Florence Emilie Jeanne Francoise Wauters
-
Publication number: 20210187090Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to immunogenic compositions and vaccines comprising detoxified pneumolysin adsorbed onto aluminium phosphate and an improved process for the adsorption of detoxified pneumolysin onto aluminium phosphate. It additionally relates to the use of the immunogenic compositions and vaccines in the treatment or prevention of Streptococcu pneumoniae infection.Type: ApplicationFiled: February 20, 2017Publication date: June 24, 2021Inventors: Laurence Danielle GHENNE, Dominique Ingrid LEMOINE, Frédéric MATHOT, Florence Emilie Jeanne Francoise WAUTERS
-
Publication number: 20200390875Abstract: Described herein is the formulation of immunogenic or vaccine compositions comprising neutral lipid liposome based adjuvants, where the composition is suitable for lyophilisation. In particular, the invention relates to lyophilised forms of such immunogenic or vaccine compositions wherein both the immunogen or vaccine antigen and the adjuvant are present in one and the same vial, as well as to the formulation and manufacture of lyophilised forms of such immunogenic or vaccine composition.Type: ApplicationFiled: May 22, 2020Publication date: December 17, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Dominique Ingrid LEMOINE, Nicolas MONIOTTE
-
Patent number: 10702594Abstract: Described herein is the formulation of immunogenic or vaccine compositions comprising neutral lipid liposome based adjuvants, where the composition is suitable for lyophilisation. In particular, the invention relates to lyophilised forms of such immunogenic or vaccine compositions wherein both the immunogen or vaccine antigen and the adjuvant are present in one and the same vial, as well as to the formulation and manufacture of lyophilised forms of such immunogenic or vaccine composition.Type: GrantFiled: December 13, 2016Date of Patent: July 7, 2020Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Dominique Ingrid Lemoine, Nicolas Moniotte
-
Patent number: 10441648Abstract: Immunogenic compositions comprising an M72 related antigen, wherein the conductivity of the composition is 13 mS/cm or lower, or the concentration of salts of the composition is 130 mM or lower, and their use in medicine, are provided.Type: GrantFiled: July 6, 2017Date of Patent: October 15, 2019Assignee: GlaxoSmithKline Biologicals SAInventors: Stéphane André Georges Godart, Amina Laanan, Dominique Ingrid Lemoine
-
Publication number: 20190183998Abstract: Immunogenic compositions comprising an M72 related antigen, wherein the conductivity of the composition is 13 mS/cm or lower, or the concentration of salts of the composition is 130 mM or lower, and their use in medicine, are provided.Type: ApplicationFiled: February 8, 2019Publication date: June 20, 2019Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventors: Stephane Andre Georges GODART, Amina LAANAN, Dominique Ingrid LEMOINE
-
Publication number: 20180360939Abstract: Described herein is the formulation of immunogenic or vaccine compositions comprising neutral lipid liposome based adjuvants, where the composition is suitable for lyophilisation. In particular, the invention relates to lyophilised forms of such immunogenic or vaccine compositions wherein both the immunogen or vaccine antigen and the adjuvant are present in one and the same vial, as well as to the formulation and manufacture of lyophilised forms of such immunogenic or vaccine composition.Type: ApplicationFiled: December 13, 2016Publication date: December 20, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS, SAInventors: Dominique Ingrid LEMOINE, Nicolas MONIOTTE
-
Publication number: 20180071378Abstract: Immunogenic compositions comprising an M72 related antigen, wherein the conductivity of the composition is 13 mS/cm or lower, or the concentration of salts of the composition is 130 mM or lower, and their use in medicine, are provided.Type: ApplicationFiled: July 6, 2017Publication date: March 15, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS, SAInventors: Stéphane André Georges GODART, Amina LAANAN, Dominique Ingrid LEMOINE
-
Publication number: 20180021417Abstract: The present invention relates to an aqueous adjuvant composition comprising a TLR-4 agonist and a saponin in a liposomal formulation and a non-ionic isotonicity agent having low salt concentrations.Type: ApplicationFiled: July 10, 2017Publication date: January 25, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS, SAInventors: Veronique Henderickx, Dominique Ingrid Lemoine
-
Patent number: 9730992Abstract: Immunogenic compositions comprising an M72 related antigen, wherein the conductivity of the composition is 13 mS/cm or lower, or the concentration of salts of the composition is 130 mM or lower, and their use in medicine, are provided.Type: GrantFiled: December 14, 2011Date of Patent: August 15, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Stéphane André Georges Godart, Amina Laanan, Dominique Ingrid Lemoine
-
Publication number: 20160220656Abstract: Immunogenic compositions comprising an Rv1196 related antigen, wherein the conductivity of the composition is 13 mS/cm or lower, or the concentration of salts of the composition is 130 mM or lower, and their use in medicine, are provided.Type: ApplicationFiled: April 18, 2016Publication date: August 4, 2016Inventors: Stephane Andre Georges GODART, Amina LAANAN, Dominique Ingrid LEMOINE
-
Patent number: 9352030Abstract: Immunogenic compositions comprising an Rv1196 related antigen, wherein the conductivity of the composition is 13 mS/cm or lower, or the concentration of salts of the composition is 130 mM or lower, and their use in medicine, are provided.Type: GrantFiled: December 14, 2011Date of Patent: May 31, 2016Assignee: GlaxoSmithKline Biologicals, S.A.Inventors: Stéphane André Georges Godart, Amina Laanan, Dominique Ingrid Lemoine
-
Publication number: 20140234424Abstract: Methods and processes for the purification of PRAME are provided. In particular, methods for reducing the aggregation of PRAME during a diluent exchange from diluent A to diluent B comprising: (i) adding a polyanionic compound to diluent A prior to or contemporaneously with the exchange; and (ii) exchanging protein from diluent A to diluent B are provided. Compositions produced by the method are also provided.Type: ApplicationFiled: July 20, 2012Publication date: August 21, 2014Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Olivier C Germay, Stephane Andre Godart, Pol Guy Harvengt, Amina Laanan, Olivier Patrick Le Bussy, Dominique Ingrid Lemoine, Leonard Dode
-
Publication number: 20140193481Abstract: A component for a HIV vaccine comprising: a) an immunogenic fusion protein comprising Nef or an immunogenic fragment or derivative thereof, and p17 Gag and/or p24 Gag or immunogenic fragments or derivatives thereof, wherein when both p17 and p24 Gag are present there is at least one HIV antigen or immunogenic fragment between them, and b) a stabilising agent selected from the group comprising or consisting of monothioglycerol, cysteine, N-acetyl cysteine or mixtures thereof. The invention also extends to HIV vaccines comprising the same and use in treatment/prevention of HIV.Type: ApplicationFiled: November 21, 2013Publication date: July 10, 2014Applicant: GlaxoSmithKline Biologicals, s.a.Inventors: Dominique Ingrid LEMOINE, Sophie Valerie Anne Ponsard
-
Publication number: 20140112953Abstract: The present invention provides formulations of an immunogenic composition containing a purified inactivated Dengue virus, and method for producing them.Type: ApplicationFiled: May 25, 2012Publication date: April 24, 2014Applicant: Glaxo SmithKline Biologicals saInventors: Veronique Henderickx, Olivier Le Bussy, Dominique Ingrid Lemoine, Frederic Mathot
-
Publication number: 20130287809Abstract: Immunogenic compositions comprising an Rv1196 related antigen, wherein the conductivity of the composition is 13 mS/cm or lower, or the concentration of salts of the composition is 130 mM or lower, and their use in medicine, are provided.Type: ApplicationFiled: December 14, 2011Publication date: October 31, 2013Applicant: GlaxoSmithKline Biologicals s.a.Inventors: Stéphane André Georges Godart, Amina Laanan, Dominique Ingrid Lemoine
-
Publication number: 20130280289Abstract: Immunogenic compositions comprising an M72 related antigen, wherein the conductivity of the composition is 13 mS/cm or lower, or the concentration of salts of the composition is 130 mM or lower, and their use in medicine, are provided.Type: ApplicationFiled: December 14, 2011Publication date: October 24, 2013Applicant: GlaxoSmithKline Biologicals s.a.Inventors: Stéphane André Georges Godart, Amina Laanan, Dominique Ingrid Lemoine
-
Patent number: 8557247Abstract: The present invention provides lyophilised compositions comprising an antigen and a Toll-like receptor (TLR) 9 agonist. Such compositions may be reconstituted into immunogenic compositions for use in vaccination with a carrier selected from the group of particulate carriers consisting of liposomes, mineral salts, emulsions, polymers and ISCOMs. Methods of making immunogenic compositions from the lyophilised compositions of the invention and use of the same in immunisation are also herein provided.Type: GrantFiled: November 15, 2010Date of Patent: October 15, 2013Assignee: GlaxoSmithKline Biologicals SAInventor: Dominique Ingrid Lemoine